Arbutus Biopharma Corporation logo

Arbutus Biopharma Corporation (ABUS) Q1 2026 Earnings

ABUS·Reported May 13, 2026·Before market open

Arbutus Biopharma Corporation reported Q1 2026 revenue of $179.1M (+10054.5% YoY), beat analyst consensus of $750.0K by $178.4M. Diluted EPS came in at $0.87, beat the $-0.03 consensus by $0.90.

Revenue
$179.1Mbeat by $178.4M
Consensus: $750.0K
Diluted EPS
$0.87beat by $0.90
Consensus: $-0.03
SEC

SEC Filings

Earnings release8-K · 0001171843-26-003346
Quarterly report10-Q · 0001447028-26-000021

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Arbutus Biopharma Corporation's Q1 2026 earnings report.

Arbutus Biopharma Corporation (ABUS) reported Q1 2026 earnings on May 13, 2026 before market open.

Arbutus Biopharma Corporation reported revenue of $179.1M and diluted EPS of $0.87 for Q1 2026.

Revenue beat the consensus estimate of $750.0K by $178.4M. EPS beat the consensus estimate of $-0.03 by $0.90.

Compared to the same quarter a year prior, revenue grew 10054.5% from $1.8M a year earlier.

You can read the 8-K earnings release (0001171843-26-003346) and the 10-Q periodic report (0001447028-26-000021) directly on SEC EDGAR. The filing index links above go to sec.gov.